These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation.
    Author: Ito H, Ito H, Nakano S, Kusaka H.
    Journal: Acta Neurol Scand; 2007 Apr; 115(4):271-4. PubMed ID: 17376126.
    Abstract:
    OBJECTIVE: To investigate the efficacy of low dose of botulinum toxin type A (BTX-A) for facial synkinesis and hyperlacrimation. MATERIAL AND METHODS: Eleven patients suffering from facial synkinesis after Bell's palsy or facial nerve injury were treated with a low dose of BTX-A, 0.5-1.25 U per point into several points. One patient showing hyperlacrimation was also treated with BTX-A. The whole observational period was 43 months. RESULTS: On average, 5.76 U of BTX-A, which was lower than that of previous reports, was injected per treatment. In seven cases, synkinesis disappeared completely after three or fewer sessions of BTX-A injection. The mean interval between treatments was 14.5 weeks. Hyperlacrimation was completely suppressed after a single subcutaneous injection of BTX-A. Only mild subcutaneous hemorrhage was observed as adverse reactions. CONCLUSION: Facial synkinesis can be treated with a lower dose of BTX-A without relevant adverse reactions.
    [Abstract] [Full Text] [Related] [New Search]